- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07828119
The Effect of a Hybrid Approach in Breast Cancer Education on Women's Awareness, Fatalism, and Self-Compassion Levels: A Randomized Controlled Trial
15. september 2026 oppdatert av: Emine Aksut Akcay, Kahramanmaras Sutcu Imam University
This randomized controlled trial aims to evaluate the effect of a hybrid breast cancer education program on women's breast cancer awareness, cancer fatalism, and self-compassion levels.
The study will include 128 women aged 20-65 who apply to an obstetrics and gynecology outpatient clinic.
Participants will be randomly assigned to either an experimental group or a control group.
The experimental group will receive a hybrid education model.
This model consists of a face-to-face training session using a breast model, followed by four weeks of educational materials, informative messages, and reminders delivered via a mobile application.
The control group will receive routine healthcare services without this specific educational intervention.
Researchers will measure the participants' levels of self-compassion, breast cancer fatalism, and breast cancer awareness using standardized questionnaires.
These measurements will be taken at the beginning of the study (pre-test) and four weeks later (post-test) to determine if the technology-supported hybrid education model is effective in improving early diagnosis awareness and psychosocial outcomes
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Breast cancer remains the most common cancer among women globally, making early detection and screening programs a primary target for public health policies.
However, insufficient awareness and high levels of cancer fatalism can negatively impact women's participation in early diagnosis behaviors such as breast self-examination and mammography.
Additionally, self-compassion is an emerging concept in women's health associated with better psychological resilience, stress management, and adherence to health behaviors.
While digital technologies have transformed health education through hybrid models, there is a limited number of randomized controlled trials examining the combined effects of hybrid education approaches on awareness, fatalism, and self-compassion in community-based female populations.
This study is designed to address this gap in the literature.
The sample size was determined using a priori power analysis via G*Power software (MANOVA: Repeated measures, within-between interaction), calculating a minimum of 128 participants based on an effect size of f(V)=0.25,
α=0.05, and test power of 0.80.
Statistical analysis will be conducted using SPSS software.
Following normality checks via Kolmogorov-Smirnov tests and the evaluation of skewness and kurtosis coefficients, group comparisons will be performed using appropriate parametric (e.g., Independent Samples t-test) or non-parametric (e.g., Mann-Whitney U, Wilcoxon signed-rank test) statistical methods.
A p-value of <0.05 will be considered statistically significant.
Studietype
Intervensjonell
Registrering (Antatt)
128
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Emine A AKSÜT AKÇAY, Assistant Professor
- Telefonnummer: 0553594 52 60
- E-post: emineaksutakcay@ksu.edu.tr/
Studer Kontakt Backup
- Navn: Hülya KAMALAK, Master's Student
- Telefonnummer: 0553594 52 60
- E-post: hulyakoca31@windowslive.com
Studiesteder
-
-
Merkez
-
Kahramanmaraş, Merkez, Tyrkia (Türkiye), 46040
- Kahramanmaras Sutcu Imam University Hospital, Department of Obstetrics and Gynecology, Delivery Room
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Being between 20 and 65 years of age
- Being female
- Agreeing to participate in the study and signing the informed consent form
- Having no prior diagnosis of breast cancer
- Having the ability to use a mobile application
Exclusion Criteria:
- Having a prior diagnosis of breast cancer or active breast pathology
- Having any cognitive, mental, or communication barrier that prevents participation in training
- Refusing to participate or withdraw consent during the study
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Hybrid Breast Cancer Education Group
The experimental group will receive a hybrid breast cancer education model consisting of a face-to-face training session using a breast model, followed by educational materials, informative messages, and reminders delivered via a mobile application over a four-week period.
|
The experimental group will receive a hybrid breast cancer education model consisting of a face-to-face training session using a breast model, followed by educational materials, informative messages, and reminders delivered via a mobile application over a four-week period
|
|
Ingen inngripen: Control Group
Participants in the control group will not receive the hybrid breast cancer education intervention during the study period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Breast Cancer Awareness Score
Tidsramme: Baseline and 4 weeks post-intervention
|
Change in participants' breast cancer awareness scores from baseline to 4 weeks post-intervention.
|
Baseline and 4 weeks post-intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
15. september 2026
Primær fullføring (Antatt)
31. desember 2026
Studiet fullført (Antatt)
31. desember 2026
Datoer for studieregistrering
Først innsendt
3. september 2026
Først innsendt som oppfylte QC-kriteriene
15. september 2026
Først lagt ut (Faktiske)
18. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- KSU-TAREK-244
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Individual participant data will not be shared to protect participant confidentiality and privacy in accordance with the ethical approval terms.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .